Patents by Inventor Scott R. Presnell

Scott R. Presnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
    Patent number: 11866466
    Abstract: Peptide-immuno-oncology agent complexes (“peptide-I/O complexes”) that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: January 9, 2024
    Assignee: BLAZE BIOSCIENCE, INC.
    Inventors: Natalie Winblade Nairn, Julia Novak, Kenneth Grabstein, Dennis Miller, Greg T. Hermanson, Scott R. Presnell, Mark Stroud
  • ANTIBODY HEAVY CHAIN CONSTANT DOMAINS
    Publication number: 20220185877
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: January 7, 2022
    Publication date: June 16, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • Methods of treatment using IL-23p19 monoclonal antibodies
    Patent number: 11254740
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: February 22, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • TUMOR HOMING AND CELL PENETRATING PEPTIDE-IMMUNO-ONCOLOGY AGENT COMPLEXES AND METHODS OF USE THEREOF
    Publication number: 20210130419
    Abstract: Peptide-immuno-oncology agent complexes (“peptide-I/O complexes”) that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.
    Type: Application
    Filed: December 18, 2018
    Publication date: May 6, 2021
    Inventors: Natalie Winblade NAIRN, Julia NOVAK, Kenneth GRABSTEIN, Dennis MILLER, Greg T. HERMANSON, Scott R. PRESNELL, Mark STROUD
  • Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases
    Patent number: 10640575
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: May 5, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Treating inflammation with IL-17/IL-23 bispecific antibodies
    Patent number: 10562967
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 18, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • METHODS OF TREATMENT USING IL-23p19 MONOCLONAL ANTIBODIES
    Publication number: 20200040072
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: June 10, 2019
    Publication date: February 6, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies
    Patent number: 10358490
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • IL-23p19 monoclonal antibodies
    Patent number: 10358489
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: July 23, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • USE OF IL-17A AND IL-17F CROSS-REACTIVE MONOCLONAL ANTIBODIES FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20180282433
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: June 15, 2018
    Publication date: October 4, 2018
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • POLYNUCLEOTIDES ENCODING MONOCLONAL ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F
    Publication number: 20180251543
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 6, 2018
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • TREATING INFLAMMATION WITH IL-17/IL-23 BISPECIFIC ANTIBODIES
    Publication number: 20180251541
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies
    Patent number: 10023656
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: July 17, 2018
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Monoclonal antibodies that bind both IL-17A and IL-17F
    Patent number: 10000563
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: June 19, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Use of an IL-17/IL-23 bispecific antibody for treating inflammation
    Patent number: 9994634
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 12, 2018
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • IL-17A/F AND IL-23p19 BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20180037645
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 8, 2018
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies
    Patent number: 9783606
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 10, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • IL-23p19 MONOCLONAL ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20170275357
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: June 12, 2017
    Publication date: September 28, 2017
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • METHODS OF TREATING INFLAMMATION USING IL-17A AND IL-17F CROSS-REACTIVE MONOCLONAL ANTIBODIES
    Publication number: 20170233498
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Compositions and methods for inhibiting PDGFRbeta and VEGF-A
    Patent number: 9708390
    Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: July 18, 2017
    Assignee: ZYMOGENETICS, INC.
    Inventors: Pallavur V. Sivakumar, Debra G. Gilbertson, Marshall D. Snavely, George R. Mabry, Eugene C. Yi, Yue Yao, Scott R. Presnell